---
layout: post
title: "Cross Labeling Oncology Drugs in Combination Regimens; Guidance for Industry; Availability"
date: 2026-02-05 19:01:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-23866
original_published: 2022-11-03 00:00:00 +0000
significance: 8.00
---

# Cross Labeling Oncology Drugs in Combination Regimens; Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 03, 2022 00:00 UTC
**Document Number:** 2022-23866

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Cross Labeling Oncology Drugs in Combination Regimens." This guidance describes FDA's current recommendations on including relevant information in labeling for oncology drugs approved for use in combination regimens. This guidance finalizes the draft guidance of the same title issued on November 20, 2020.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/03/2022-23866/cross-labeling-oncology-drugs-in-combination-regimens-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-23866

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
